Prothena Corp (PRTA)

$9.59 +0.13 (1.37%)
Market Cap 516.26M
Revenue (ttm) 9.68M
Net Income (ttm) -244.09M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 25.99
Profit Margin -2,521.59%
Debt to Equity Ratio 0.00
Volume 651,700
Avg Vol 479,824
Day's Range N/A - N/A
Shares Out 53.83M
Stochastic %K 70%
Beta -0.24
Analysts Sell
Price Target $20.50

Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of tr...

Industry: Biotechnology
Sector: Healthcare
Phone: 353 1 236 2500
Fax: 353 1 902 3510
Address:
77 Sir John Rogerson’s Quay, Block C Grand Canal Docklands, Dublin, Ireland
Itinerant
Itinerant Mar. 6 at 7:34 PM
$PRTA I am newly looking at this company. I do not understand why it has such a large market cap. It seems over valued to me. Perhaps it is just that it has two BP partners. However, there are other players in Parkinson's so that does not particularly impress me unless there is tech that I do not understand. Please give me some constructive input.
0 · Reply
buyandsold
buyandsold Mar. 4 at 10:02 PM
$PRTA actively holding. Does that make me watching part 3?
1 · Reply
takingstock73
takingstock73 Mar. 4 at 7:58 PM
$PRTA watching too
0 · Reply
MasterOfMyDomains
MasterOfMyDomains Feb. 27 at 9:29 PM
$PRTA watching.....
1 · Reply
UgoGreg
UgoGreg Feb. 26 at 8:20 PM
$PRTA https://youtu.be/AJ2YEtCMhiI
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 21 at 11:05 AM
$PRTA RSI: 55.22, MACD: -0.1156 Vol: 0.40, MA20: 9.06, MA50: 9.32 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
ZacksResearch
ZacksResearch Feb. 20 at 6:45 PM
$PRTA earnings met… but is that enough? 👀 Q4 loss narrowed year over year, showing some progress, but revenues missed estimates. Now the real focus shifts to its outlined 2026 cash burn guidance and upcoming key milestones from partners — that’s where the next move could be decided. Is this a setup year or a turning point? Full breakdown here 👉 https://www.zacks.com/stock/news/2872993/prothena-q4-earnings-meet-estimates-pipeline-progress-in-focus?cid=sm-stocktwits-2-2872993-teaser-34515&ADID=SYND_STOCKTWITS_TWEET_2_2872993_TEASER_34515
0 · Reply
ZacksResearch
ZacksResearch Feb. 20 at 5:45 PM
$PRTA Q4 earnings reveal: Is the biotech’s slide over? 🤔 The company matched EPS expectations with a loss of 45 cents but missed revenue estimates, reporting $0.02M against the expected $3.0M. 📉 Full-year revenues for 2025 plunged 93% YoY, and shares have dropped 42% over the past year. Fundamental insights here 👉 https://www.zacks.com/stock/news/2872993/prothena-q4-earnings-meet-estimates-pipeline-progress-in-focus?cid=sm-stocktwits-2-2872993-body-34514&ADID=SYND_STOCKTWITS_TWEET_2_2872993_BODY_34514
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 19 at 9:13 PM
$PRTA Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.40 up 62.96% YoY • Reported revenue of $0.02M down -99.01% YoY • Prothena anticipates full year 2026 net cash used in operating and investing activities of $50M, with an estimated $255M cash balance, largely due to a projected net loss of $67M.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 19 at 9:13 PM
$PRTA Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.40 up 62.96% YoY • Reported revenue of $0.02M down -99.01% YoY • Prothena expects full year 2026 net cash used in operating and investing activities to be $50 to $55M, ending the year with approximately $255M in cash (midpoint), not including up to $105M in clinical milestone payments.
0 · Reply
Latest News on PRTA
Prothena: A Hold With 2 Late-Stage Programs Underway But With Caution

Mar 3, 2026, 1:50 PM EST - 5 days ago

Prothena: A Hold With 2 Late-Stage Programs Underway But With Caution

Prothena Announces up to $100 Million Share Repurchase Plan

Feb 27, 2026, 4:15 PM EST - 9 days ago

Prothena Announces up to $100 Million Share Repurchase Plan

Prothena Corporation plc (PRTA) Q4 2025 Earnings Call Transcript

Feb 19, 2026, 9:24 PM EST - 17 days ago

Prothena Corporation plc (PRTA) Q4 2025 Earnings Call Transcript

Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights

Feb 19, 2026, 4:05 PM EST - 17 days ago

Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights

Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026

Feb 12, 2026, 4:05 PM EST - 24 days ago

Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026

Prothena Announces Board of Directors Update

Dec 12, 2025, 4:05 PM EST - 3 months ago

Prothena Announces Board of Directors Update

Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025

Nov 19, 2025, 4:05 PM EST - 3 months ago

Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025

Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA

Nov 11, 2025, 9:00 AM EST - 4 months ago

Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA

Prothena Reports Third Quarter 2025 Financial Results and Business Highlights

Nov 6, 2025, 4:05 PM EST - 4 months ago

Prothena Reports Third Quarter 2025 Financial Results and Business Highlights

Prothena to Report Third Quarter 2025 Financial Results on November 6

Oct 30, 2025, 4:05 PM EDT - 4 months ago

Prothena to Report Third Quarter 2025 Financial Results on November 6

Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's Disease

Oct 1, 2025, 4:45 PM EDT - 5 months ago

Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's Disease

Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference

Aug 28, 2025, 4:05 PM EDT - 6 months ago

Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference

Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program

Aug 27, 2025, 4:05 PM EDT - 6 months ago

Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program

Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy

Aug 6, 2025, 9:00 AM EDT - 7 months ago

Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy

Prothena Reports Second Quarter 2025 Financial Results and Business Highlights

Aug 4, 2025, 4:05 PM EDT - 7 months ago

Prothena Reports Second Quarter 2025 Financial Results and Business Highlights

Prothena to Report Second Quarter 2025 Financial Results on August 4

Jul 28, 2025, 4:05 PM EDT - 7 months ago

Prothena to Report Second Quarter 2025 Financial Results on August 4

Prothena Announces Corporate Restructuring

Jun 18, 2025, 4:05 PM EDT - 9 months ago

Prothena Announces Corporate Restructuring

Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease

Jun 16, 2025, 1:06 AM EDT - 9 months ago

Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease

Why Is Prothena Stock Trading Lower On Tuesday?

May 27, 2025, 7:43 AM EDT - 10 months ago

Why Is Prothena Stock Trading Lower On Tuesday?

Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint

May 23, 2025, 4:05 PM EDT - 10 months ago

Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint

Top 3 Health Care Stocks That Are Preparing To Pump This Quarter

May 9, 2025, 7:16 AM EDT - 10 months ago

Top 3 Health Care Stocks That Are Preparing To Pump This Quarter

RXST SRPT

Prothena Reports First Quarter 2025 Financial Results and Business Highlights

May 8, 2025, 4:05 PM EDT - 10 months ago

Prothena Reports First Quarter 2025 Financial Results and Business Highlights

Prothena to Report First Quarter 2025 Financial Results on May 8

May 1, 2025, 4:05 PM EDT - 11 months ago

Prothena to Report First Quarter 2025 Financial Results on May 8

Prothena Corporation plc (PRTA) Q4 2024 Earnings Call Transcript

Feb 20, 2025, 8:45 PM EST - 1 year ago

Prothena Corporation plc (PRTA) Q4 2024 Earnings Call Transcript

Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights

Feb 20, 2025, 4:05 PM EST - 1 year ago

Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights

Kuehn Law Encourages Investors of Prothena Corporation PLC to Contact Law Firm

Feb 17, 2025, 6:10 PM EST - 1 year ago

Kuehn Law Encourages Investors of Prothena Corporation PLC to Contact Law Firm

Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

Feb 13, 2025, 4:05 PM EST - 1 year ago

Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

Roche's Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson's Disease

Dec 19, 2024, 1:05 AM EST - 1 year ago

Roche's Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson's Disease

Prothena Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 12, 2024, 4:05 PM EST - 1 year ago

Prothena Reports Third Quarter 2024 Financial Results and Business Highlights

Prothena to Report Third Quarter 2024 Financial Results on November 12

Nov 5, 2024, 4:05 PM EST - 1 year ago

Prothena to Report Third Quarter 2024 Financial Results on November 12

Prothena Announces Leadership Team Updates

Sep 27, 2024, 4:05 PM EDT - 1 year ago

Prothena Announces Leadership Team Updates

Prothena to Participate in Upcoming Healthcare Conferences

Aug 29, 2024, 4:05 PM EDT - 1 year ago

Prothena to Participate in Upcoming Healthcare Conferences

Prothena Reports Second Quarter 2024 Financial Results and Business Highlights

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Prothena Reports Second Quarter 2024 Financial Results and Business Highlights

Prothena to Report Second Quarter 2024 Financial Results on August 8

Aug 1, 2024, 4:05 PM EDT - 1 year ago

Prothena to Report Second Quarter 2024 Financial Results on August 8

Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration

May 28, 2024, 4:05 PM EDT - 1 year ago

Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration

Prothena Reports First Quarter 2024 Financial Results and Business Highlights

May 8, 2024, 4:05 PM EDT - 1 year ago

Prothena Reports First Quarter 2024 Financial Results and Business Highlights

Prothena to Report First Quarter 2024 Financial Results on May 8

May 1, 2024, 4:05 PM EDT - 2 years ago

Prothena to Report First Quarter 2024 Financial Results on May 8

Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma

Apr 15, 2024, 4:05 PM EDT - 2 years ago

Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma

Prothena Appoints David Ford to Newly Created Chief People Officer Position

Mar 4, 2024, 4:05 PM EST - 2 years ago

Prothena Appoints David Ford to Newly Created Chief People Officer Position

Prothena: Alzheimer's Data Update In 2024 Could Move The Needle

Feb 23, 2024, 12:31 PM EST - 2 years ago

Prothena: Alzheimer's Data Update In 2024 Could Move The Needle

Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate

Feb 21, 2024, 4:05 PM EST - 2 years ago

Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate

Prothena Corporation plc (PRTA) Q4 2023 Earnings Call Transcript

Feb 15, 2024, 11:53 PM EST - 2 years ago

Prothena Corporation plc (PRTA) Q4 2023 Earnings Call Transcript

Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights

Feb 15, 2024, 4:05 PM EST - 2 years ago

Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights

Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024

Feb 8, 2024, 4:05 PM EST - 2 years ago

Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024

Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs

Jan 8, 2024, 8:30 AM EST - 2 years ago

Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs

Prothena Reports Third Quarter 2023 Financial Results and Business Highlights

Nov 2, 2023, 4:05 PM EDT - 2 years ago

Prothena Reports Third Quarter 2023 Financial Results and Business Highlights

Prothena to Report Third Quarter 2023 Financial Results on November 2

Oct 26, 2023, 4:05 PM EDT - 2 years ago

Prothena to Report Third Quarter 2023 Financial Results on November 2

Prothena prepares for potential sale - Bloomberg News

Oct 16, 2023, 11:57 AM EDT - 2 years ago

Prothena prepares for potential sale - Bloomberg News

Prothena: Switching From 'Hold' To 'Buy' On Lead Alzheimer's Drug Promise

Sep 21, 2023, 1:39 PM EDT - 2 years ago

Prothena: Switching From 'Hold' To 'Buy' On Lead Alzheimer's Drug Promise

Prothena Reports Second Quarter 2023 Financial Results and Business Highlights

Aug 3, 2023, 4:05 PM EDT - 2 years ago

Prothena Reports Second Quarter 2023 Financial Results and Business Highlights

Itinerant
Itinerant Mar. 6 at 7:34 PM
$PRTA I am newly looking at this company. I do not understand why it has such a large market cap. It seems over valued to me. Perhaps it is just that it has two BP partners. However, there are other players in Parkinson's so that does not particularly impress me unless there is tech that I do not understand. Please give me some constructive input.
0 · Reply
buyandsold
buyandsold Mar. 4 at 10:02 PM
$PRTA actively holding. Does that make me watching part 3?
1 · Reply
takingstock73
takingstock73 Mar. 4 at 7:58 PM
$PRTA watching too
0 · Reply
MasterOfMyDomains
MasterOfMyDomains Feb. 27 at 9:29 PM
$PRTA watching.....
1 · Reply
UgoGreg
UgoGreg Feb. 26 at 8:20 PM
$PRTA https://youtu.be/AJ2YEtCMhiI
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 21 at 11:05 AM
$PRTA RSI: 55.22, MACD: -0.1156 Vol: 0.40, MA20: 9.06, MA50: 9.32 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
ZacksResearch
ZacksResearch Feb. 20 at 6:45 PM
$PRTA earnings met… but is that enough? 👀 Q4 loss narrowed year over year, showing some progress, but revenues missed estimates. Now the real focus shifts to its outlined 2026 cash burn guidance and upcoming key milestones from partners — that’s where the next move could be decided. Is this a setup year or a turning point? Full breakdown here 👉 https://www.zacks.com/stock/news/2872993/prothena-q4-earnings-meet-estimates-pipeline-progress-in-focus?cid=sm-stocktwits-2-2872993-teaser-34515&ADID=SYND_STOCKTWITS_TWEET_2_2872993_TEASER_34515
0 · Reply
ZacksResearch
ZacksResearch Feb. 20 at 5:45 PM
$PRTA Q4 earnings reveal: Is the biotech’s slide over? 🤔 The company matched EPS expectations with a loss of 45 cents but missed revenue estimates, reporting $0.02M against the expected $3.0M. 📉 Full-year revenues for 2025 plunged 93% YoY, and shares have dropped 42% over the past year. Fundamental insights here 👉 https://www.zacks.com/stock/news/2872993/prothena-q4-earnings-meet-estimates-pipeline-progress-in-focus?cid=sm-stocktwits-2-2872993-body-34514&ADID=SYND_STOCKTWITS_TWEET_2_2872993_BODY_34514
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 19 at 9:13 PM
$PRTA Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.40 up 62.96% YoY • Reported revenue of $0.02M down -99.01% YoY • Prothena anticipates full year 2026 net cash used in operating and investing activities of $50M, with an estimated $255M cash balance, largely due to a projected net loss of $67M.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 19 at 9:13 PM
$PRTA Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.40 up 62.96% YoY • Reported revenue of $0.02M down -99.01% YoY • Prothena expects full year 2026 net cash used in operating and investing activities to be $50 to $55M, ending the year with approximately $255M in cash (midpoint), not including up to $105M in clinical milestone payments.
0 · Reply
Estimize
Estimize Feb. 19 at 4:00 PM
$PRTA reports after the close, Estimize Consensus -0.15 EPS and -0M Revs compared to WS http://www.estimize.com/prta/fq4-2025?utm_content=p
0 · Reply
TradeSurveyor
TradeSurveyor Feb. 18 at 10:30 AM
$PRTA Rare disease biotech with regulatory catalysts.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 17 at 10:45 PM
$PRTA Current Stock Price: $8.96 Contracts to trade: $9.0 PRTA Feb 20 2026 Call Entry: $0.36 Exit: $0.62 ROI: 73% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Estimize
Estimize Feb. 12 at 9:00 PM
Wall St is expecting -0.33 EPS for $PRTA Q1 [Reporting 05/13 AMC] http://www.estimize.com/intro/prta?chart=historical&metric_name=eps&utm_c
0 · Reply
EthelStiles316
EthelStiles316 Feb. 11 at 4:12 PM
$PRTA Prothena; neuroscience biotech; partnered with BMS, Roche; clinical-stage; binary readouts; amyloid franchise.
0 · Reply
buyandsold
buyandsold Jan. 30 at 8:10 PM
$PRTA really sucks I didnt sell at $11
0 · Reply
Fugazi_
Fugazi_ Jan. 28 at 8:05 AM
$PRTA when is the next data release in their pipe? cant find anything
1 · Reply
BillionerOfKing
BillionerOfKing Jan. 19 at 6:01 PM
$PRTA Current Stock Price: $9.35 Contracts to trade: $10 PRTA Feb 20 2026 Call Entry: $0.20 Exit: $0.39 ROI: 97% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
buyandsold
buyandsold Jan. 15 at 3:39 PM
$PRTA i should have trimmed when this was 1/3 of port. But I do see clear path to $30
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 14 at 4:09 AM
$PRTA RSI: 34.91, MACD: -0.2985 Vol: 0.29, MA20: 9.35, MA50: 10.01 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
buyandsold
buyandsold Jan. 2 at 12:36 PM
$PRTA let's retake $11 in January as funds load up for sales of some assets with special dividends to follow.
1 · Reply
PaperWalletP4
PaperWalletP4 Dec. 26 at 4:23 PM
$PRTA Capital is flowing toward execution strength rather than speculative optionality. Forecast discipline should become more precise and conservative. Sustained traction could validate the investment case. Upside remains tied to tangible progress, not assumptions.
0 · Reply